Core Viewpoint - The Hong Kong stock market is experiencing a significant surge in new stock listings, with notable gains observed in the initial trading days of these stocks, indicating a strong investor interest and profitability potential in the market [1][9]. Group 1: New Stock Performance - Wangshan Wangshui-B (02630.HK) is set to list on November 6, with its stock price soaring to 97 HKD per share during the dark trading phase, reflecting an increase of over 190% at one point [1][2]. - The stock closed at 85 HKD per share in the dark trading, marking a 154.72% rise from its offering price of 33.37 HKD per share, potentially yielding a profit of 10,300 HKD per lot (200 shares) for investors [1][3]. - Among the 14 new stocks listed in October, only one experienced a decline on its first trading day, while others saw substantial gains, with Jin Ye International Group achieving a remarkable 330% increase [9]. Group 2: Company Overview - Wangshan Wangshui, established in 2013, is a biopharmaceutical company with nine innovative drug pipelines, including two in commercialization, four in clinical stages, and three in preclinical stages [5]. - The company's core products include LV232, aimed at treating severe depression, and TPN171, a PDE5 inhibitor for erectile dysfunction (ED), with market projections indicating a stable growth in the PDE5 inhibitor market [5][6]. Group 3: Financial Performance - For the fiscal years 2023 and 2024, Wangshan Wangshui reported revenues of 200 million CNY and 11.83 million CNY, with net profits of 64.27 million CNY and a loss of 21.8 million CNY, respectively [7]. - The company attributed its 2024 net loss to a significant decrease in external licensing income, while the first four months of 2025 showed a further loss due to increased administrative expenses related to a new restricted stock plan [7]. Group 4: Market Trends - The Hong Kong stock market has seen a doubling of average daily trading volume to over 32 billion USD compared to the previous year, with 80 IPOs raising over 26 billion USD in the first ten months of the year, leading to a global ranking in IPO fundraising [9][10]. - Continuous inflow of southbound funds, which reached 1.17 trillion HKD by the end of Q3, is significantly enhancing the pricing power of the Hong Kong stock market, with long-term institutional investments expected to support a sustained upward trend [10][11].
刚刚，暴涨超190%！港股，异动！